Bone Morphogenetic Protein Receptors, Type II
"Bone Morphogenetic Protein Receptors, Type II" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A subtype of bone morphogenetic protein receptors with low affinity for BONE MORPHOGENETIC PROTEINS. They are constitutively active PROTEIN-SERINE-THREONINE KINASES that can interact with and phosphorylate TYPE I BONE MORPHOGENETIC PROTEIN RECEPTORS.
| Descriptor ID |
D052006
|
| MeSH Number(s) |
D08.811.913.696.620.682.700.109.750 D12.776.543.750.750.400.049.750
|
| Concept/Terms |
Bone Morphogenetic Protein Receptors, Type II- Bone Morphogenetic Protein Receptors, Type II
- BMP Type II Receptors
- Receptor, Type II BMP
- BMPR2 Receptor
- Receptor, BMPR2
- Bone Morphogenetic Protein Receptor II
- Bone Morphogenetic Protein Receptor Type II
- BMP Type II Receptor
- BMPR-II Receptor
- BMPR II Receptor
- Receptor, BMPR-II
|
Below are MeSH descriptors whose meaning is more general than "Bone Morphogenetic Protein Receptors, Type II".
Below are MeSH descriptors whose meaning is more specific than "Bone Morphogenetic Protein Receptors, Type II".
This graph shows the total number of publications written about "Bone Morphogenetic Protein Receptors, Type II" by people in this website by year, and whether "Bone Morphogenetic Protein Receptors, Type II" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 0 | 1 | 1 |
| 2012 | 0 | 1 | 1 |
| 2013 | 1 | 0 | 1 |
| 2014 | 3 | 0 | 3 |
| 2016 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
| 2020 | 1 | 1 | 2 |
| 2023 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Bone Morphogenetic Protein Receptors, Type II" by people in Profiles.
-
Reduced FOXF1 links unrepaired DNA damage to pulmonary arterial hypertension. Nat Commun. 2023 Nov 21; 14(1):7578.
-
Discovery of Highly Potent and BMPR2-Selective Kinase Inhibitors Using DNA-Encoded Chemical Library Screening. J Med Chem. 2023 02 09; 66(3):2143-2160.
-
PPAR?-p53-Mediated Vasculoregenerative Program to Reverse Pulmonary Hypertension. Circ Res. 2021 02 05; 128(3):401-418.
-
Spatiotemporal expression of activin receptor-like kinase-5 and bone morphogenetic protein receptor type II in the ovary of shortfinned eel, Anguilla australis. Comp Biochem Physiol B Biochem Mol Biol. 2021 Jan; 251:110509.
-
Opposing roles of TGF? and BMP signaling in prostate cancer development. Genes Dev. 2017 12 01; 31(23-24):2337-2342.
-
Macrophage bone morphogenic protein receptor 2 depletion in idiopathic pulmonary fibrosis and Group III pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2016 08 01; 311(2):L238-54.
-
miRNA-17 members that target Bmpr2 influence signaling mechanisms important for embryonic stem cell differentiation in vitro and gastrulation in embryos. Stem Cells Dev. 2015 Feb 01; 24(3):354-71.
-
Functional changes in pulmonary arterial endothelial cells associated with BMPR2 mutations. PLoS One. 2014; 9(9):e106703.
-
Early onset severe pulmonary arterial hypertension with 'two-hit' digenic mutations in both BMPR2 and KCNA5 genes. Int J Cardiol. 2014 Dec 20; 177(3):e167-9.
-
BMPR2 is required for postimplantation uterine function and pregnancy maintenance. J Clin Invest. 2013 Jun; 123(6):2539-50.